parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.36 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in pituicytes/fscs	0.75
chemistry Open Targets	compounds already reach it: pentoxifylline, flavoxate, dipyridamole +1	1.00
trials ClinicalTrials.gov	1 Parkinson's trial, 0 stopped	1.00
literature PubMed	3 Parkinson's papers of 90	0.82
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 0841

receipt 0850: PDE7B in dopamine neurons, braak

power: full sample +0.27 (p 0.277, n 18), 95% CI -0.22 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.21 (p 0.398, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.24 (p 0.337, n 18). could be the mix.
skeptic: leave-one-out range +0.16 to +0.40, sign flips 0; without severely affected donors +0.27 (p 0.277, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PDE7B in dopamine neurons.

case closed: nothing better to follow up.

receipt 0849: PDE7B in astrocytes, braak

power: full sample +0.14 (p 0.585, n 18), 95% CI -0.35 to +0.57. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.08 (p 0.754, n 18). could be the mix.
skeptic: leave-one-out range +0.01 to +0.27, sign flips 0; without severely affected donors +0.14 (p 0.585, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for PDE7B in astrocytes.

case closed: nothing better to follow up.

loading the receipts